Dementia is a clinical syndrome, meaning it describes a cluster of symptoms rather than a single disease with one specific cause. At the same time, doctors do write “dementia” as a diagnosis on medical charts, in insurance codes, and in conversations with families. This dual identity confuses people for good reason: the word functions as both a description of what is happening (progressive cognitive decline severe enough to disrupt daily life) and a label that triggers clinical action. Understanding which sense is being used in a given context matters, because the cause behind the syndrome shapes everything from treatment to prognosis.
Syndrome First, Disease Second
When a clinician says someone “has dementia,” they are saying the person has crossed a threshold of cognitive and functional decline. That threshold involves impairment in more than one area of thinking, such as memory, language, reasoning, or spatial awareness, combined with substantial interference in everyday activities like managing finances, cooking, or navigating familiar places.1PubMed Central. Mild cognitive impairment and mild dementia: a clinical perspective The word “dementia” captures all of that in shorthand. But it says nothing about why the decline is happening. Dozens of diseases and conditions can produce the syndrome, and identifying the right one is a separate step entirely.
This is different from, say, a diagnosis of diabetes, where the label and the disease are the same thing. Dementia is more like “fever.” Fever tells you the body temperature is abnormally high; it does not tell you whether the cause is an infection, an autoimmune flare, or a drug reaction. Similarly, dementia tells you cognition has deteriorated past a functional cliff. The work of figuring out the underlying disease comes afterward, and sometimes that work is never completed with certainty during a person’s lifetime.
The Diseases Behind the Syndrome
Alzheimer’s disease is by far the most common cause of dementia worldwide. Its hallmark pathology involves the buildup of amyloid plaques and neurofibrillary tangles in the brain, features that have been recognized for over a century and are still required for a definitive pathological diagnosis.2PubMed Central. The neuropathological diagnosis of Alzheimer’s disease Most estimates put Alzheimer’s behind roughly two-thirds of dementia cases, though the true proportion gets murkier the more carefully you look, as mixed pathology turns up frequently at autopsy.
Vascular dementia is the second most commonly cited type. It results from impaired blood flow to the brain, often following strokes. Research suggests that roughly a quarter to a third of people who survive an ischemic stroke go on to develop vascular cognitive impairment or vascular dementia, driven by damage from microinfarcts, blood-brain barrier breakdown, and focal brain atrophy.3PubMed Central. Stroke injury, cognitive impairment and vascular dementia The pattern of decline tends to differ from Alzheimer’s: it can progress in stepwise fashion after successive vascular events rather than following a gradual slope.
Dementia with Lewy bodies (DLB) involves abnormal protein deposits called Lewy bodies scattered through the brain. People with DLB often experience visual hallucinations, fluctuating alertness, and movement symptoms that overlap with Parkinson’s disease. In one autopsy-confirmed study, those with DLB and a sleep behavior disorder involving acting out dreams during REM sleep were predominantly male and tended to develop parkinsonism and hallucinations earlier in the course of the illness.4PubMed Central. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies
Frontotemporal dementia is a group of syndromes caused by degeneration of the frontal and temporal lobes. Unlike Alzheimer’s, memory is often relatively preserved early on. Instead, the first signs tend to be changes in personality, behavior, language, or executive function.5PubMed. Mixed Nonfluent/Agrammatic Primary Progressive Aphasia and Behavioral Variant Frontotemporal Dementia: A Case Report From Tanzania The underlying pathology itself divides into subgroups based on which protein accumulates in the brain, including tau, TDP-43, and FUS, and these map onto distinct clinical presentations such as the behavioral variant, progressive non-fluent aphasia, and semantic dementia.6SpringerLink / Acta Neuropathologica. Neuropathological background of phenotypical variability in frontotemporal dementia
Why “Pure” Cases Are Rarer Than You Think
One of the most underappreciated facts about dementia is how frequently more than one disease process is at work in the same brain. Autopsy studies consistently show that a neat, single-cause diagnosis is the exception among older adults, not the rule. In a large Austrian autopsy series of 1,500 people who had been diagnosed with dementia, only about 40 to 52 percent showed “pure” Alzheimer’s disease. Another 16 to 20 percent had Alzheimer’s combined with significant cerebrovascular lesions, and about 9 percent had Alzheimer’s plus Lewy body pathology.7PubMed. Neuropathological evaluation of mixed dementia These mixed cases are especially common in the oldest age groups, where the co-occurrence of Alzheimer’s pathology and vascular brain injury is the norm rather than a rarity.8PubMed Central. Clinical and imaging features of mixed Alzheimer and vascular pathologies
This matters for how you think about the original question. If dementia is a syndrome, and the diseases that cause it frequently overlap in the same person, then the clinical label “dementia” is doing even more heavy lifting than it seems. A person diagnosed with “probable Alzheimer’s dementia” during life may, at autopsy, turn out to have had Alzheimer’s plus vascular damage plus a smattering of Lewy bodies. The syndrome was accurate. The assumed single cause was not.
When the Cause Is Reversible
Not everything that looks like dementia is a progressive neurodegenerative disease. A meaningful subset of people presenting with dementia-like cognitive decline actually have conditions that can be treated, stabilized, or even reversed. The most frequently identified reversible causes include depression, adverse drug effects, alcohol or substance misuse, brain tumors or other space-occupying lesions, normal pressure hydrocephalus, hypothyroidism, and vitamin B12 deficiency.9PubMed Central. Reversible dementias
This is one of the strongest arguments for treating dementia as a syndrome that demands investigation rather than an end-point diagnosis you simply accept. When the right underlying cause is identified, treatment directed at that condition can sometimes produce partial or even complete reversal of the cognitive problems.10PubMed. Reversible dementias An older adult who seems to be developing dementia but is actually severely hypothyroid, or who is experiencing side effects from a medication, deserves a very different clinical path than someone with early Alzheimer’s. Skipping the workup and defaulting to “it’s just dementia” can mean missing a fixable problem.
Pseudodementia and the Depression Overlap
Depression in older adults deserves special mention because it mimics dementia convincingly enough to have its own clinical term: pseudodementia. The cognitive impairment in pseudodementia can look nearly identical to early-stage neurodegenerative dementia, with slowed thinking, poor concentration, difficulty with recall, and withdrawal from activities. But the cause is a psychiatric condition, most often major depression, rather than structural brain degeneration.11PubMed Central. What do we know about pseudodementia?
The distinction matters because treating the depression often restores cognition. But the picture is not always clean. Research has complicated the neat separation between pseudodementia and “real” dementia, since people who experience depressive pseudodementia are at higher risk of developing true neurodegenerative dementia later on. The term has been used somewhat loosely since it was coined in the early 1960s, and clinicians now treat it less as a distinct entity and more as a red flag that prompts closer monitoring over time.12PubMed Central. Pseudo-dementia: A neuropsychological review
How Doctors Sort It Out
Given that the word “dementia” says little about the cause, the diagnostic process is really two tasks: confirming that the syndrome is present and then figuring out why. The first part relies heavily on clinical history, cognitive testing, and input from family members about how daily functioning has changed. The second part brings in imaging and, increasingly, biological markers.
Structural brain imaging with MRI is the clinical workhorse. It is widely used and good at ruling out reversible causes like tumors or hydrocephalus, though its ability to distinguish between different types of neurodegeneration is relatively limited on its own.13Molecular Psychiatry. The use of neuroimaging techniques in the early and differential diagnosis of dementia More specialized PET scans offer finer resolution. A metabolic PET scan can show characteristic patterns of reduced brain activity: Alzheimer’s tends to produce reduced metabolism in the temporal and parietal lobes and posterior cingulate cortex, while frontotemporal dementia shows reduced metabolism in the frontal lobe, anterior cingulate, and temporal regions.14PubMed Central. The Usefulness of 18F-FDG PET to Differentiate Subtypes of Dementia: The Systematic Review and Meta-Analysis Amyloid and tau PET scans go a step further, directly detecting the protein deposits associated with Alzheimer’s disease and improving the ability to separate Alzheimer’s from non-Alzheimer’s dementias even at early stages.13Molecular Psychiatry. The use of neuroimaging techniques in the early and differential diagnosis of dementia
Advanced MRI techniques that combine measurements of brain volume, blood flow, and white-matter integrity have shown promise in differentiating dementia subtypes with high accuracy in research settings, though translating these multimodal approaches into routine clinical practice remains a work in progress.15PubMed Central. Translating state-of-the-art brain magnetic resonance imaging (MRI) techniques into clinical practice: multimodal MRI differentiates dementia subtypes in a traditional clinical setting
Blood Tests Are Catching Up
For decades, the only way to confirm Alzheimer’s-specific pathology in a living person was through a spinal tap (to measure proteins in cerebrospinal fluid) or an expensive PET scan. That is changing. Newer ultra-sensitive blood tests can now detect Alzheimer’s-related proteins in plasma with clinically useful accuracy. One particular marker, plasma p-tau217, has shown strong performance in distinguishing people with brain amyloid buildup from those without it, even in people who have not yet developed obvious symptoms.16PubMed Central. Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice
These blood-based biomarkers are significant because they could make it far easier and cheaper to move past the syndromic label of “dementia” and identify (or rule out) Alzheimer’s specifically. Right now, many people carrying a dementia diagnosis never receive a detailed etiological workup because the tools have been too expensive, too invasive, or too inaccessible outside major medical centers. A reliable blood test could shift clinical practice at scale, allowing primary care physicians to narrow down the cause without needing specialized imaging.
Before Dementia Shows Up on a Test
The recognition that neurodegenerative diseases have a long silent phase has added another layer to the question of what dementia is. In Alzheimer’s disease, amyloid deposits can start building up in the brain years or even decades before a person notices any cognitive problems. Accurately identifying this preclinical stage currently requires either cerebrospinal fluid analysis or amyloid PET imaging, which limits routine screening largely to specialized research centers.17PubMed Central. Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Recent research suggests that the late preclinical stage may not be truly “silent” after all. People at this point can develop subtle cognitive changes or a subjective sense that their thinking is not as sharp as it used to be, even when standard tests still score in the normal range.17PubMed Central. Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage This creates an awkward clinical territory: the disease is present by biological criteria, the person may notice something is off, but the syndrome of dementia has not arrived. Calling this stage “dementia” would be incorrect. Calling the person “healthy” would also miss the mark. As blood tests and other screening tools become more accessible, more people will land in this in-between zone and need a framework for understanding what it means.
How the Classification System Is Evolving
The way international coding systems define dementia has shifted recently. The transition from the ICD-10 to the ICD-11 classification kept the core syndromic framework but added refinements that reflect how the field has matured. Severity levels and the explicit coding of mental and behavioral symptoms now allow for more precise clinical descriptions. And for the first time, mild neurocognitive disorder, essentially a prodromal state sitting between normal aging and dementia, has been formally introduced as a category.18PubMed Central. Dementia: changes from ICD-10 to ICD-11
This matters because coding systems are not just administrative tools. They determine what gets counted in public health statistics, what qualifies for insurance coverage, and what clinicians are expected to document. Adding mild neurocognitive disorder as a recognized category legitimizes earlier intervention and monitoring. It also highlights the spectrum nature of cognitive decline: the boundary between “normal aging,” “mild impairment,” and “dementia” is a gradient, not a clean line, and the classification is now starting to reflect that.
The Long Evolution of Thinking About Dementia
For most of recorded history, cognitive decline in old age was considered an inevitable part of aging rather than anything resembling a medical condition. Over roughly 2,500 years, the concept evolved from a vague assumption that the mind simply deteriorated with time into a clinically defined syndrome with identifiable features, specific pathologies, and, increasingly, the realistic prospect of treatment and prevention.19PubMed. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s That trajectory helps explain why the word “dementia” still carries echoes of an older era, when it meant something closer to “loss of mind” than to a specific clinical syndrome with traceable biological causes.
The lingering confusion about whether dementia is a diagnosis or a set of symptoms partly reflects this history. For centuries, dementia was a description with no expectation of further investigation. Today it is meant to be a starting point, a syndrome-level finding that triggers a search for the underlying disease. But the word has not fully shed its older connotations, and many people, including some clinicians, still use it as though it were the final word rather than the opening question.
What Families Actually Need to Know
If you or a family member has been told “it’s dementia,” the most important follow-up question is: what kind? A diagnosis of dementia without any attempt to identify the cause is incomplete. Knowing the cause matters because it influences which medications could help, what the likely trajectory will look like, what symptoms to expect, and what support to plan for. Alzheimer’s follows a different course than Lewy body disease, which behaves differently from vascular dementia, and all of them differ from the reversible causes that might respond to treatment. Even when the underlying disease cannot be cured, knowing which one it is helps families plan, reduces confusion, and often opens access to clinical trials or disease-specific support services.
The quality of the diagnostic workup varies enormously depending on where a person lives, what specialists are available, and how aggressively the clinical team pursues the question. In some settings, a clinical history and basic cognitive screening are all that happens. In others, advanced imaging and biomarker testing produce a high-confidence etiological diagnosis. Advocating for a thorough workup, or at least asking what was ruled out and what was not, is one of the most useful things a family can do after hearing the word “dementia” for the first time.